Models attempting to quantify the relationship between drug development and financial return are missing a key element: the effect on post-approval research
{{output}}
Changes in biopharmaceutical policy, specifically the Inflation Reduction Act (IRA), introduced administrative drug price setting in the U.S., prompting questions about the impact on drug development of this and future policies under consideration. Existing mo... ...
